AuraGenix N.V. Product Pipeline is Rich in New Proprietary Anti-Aging and Aesthetic Formulations; Company Forecasts Surge in Year on Year Revenues and Earnings Commencing in Fiscal 2009

AMSTERDAM, NETHERLANDS--(Marketwire - December 31, 2008) - Ario Khoshbin, CEO and President, AuraGenix N.V. (FRANKFURT: AUI) reported today that Company fully expects to maintain double digit year on year growth in revenues and profitability from its proprietary Revanesse® brand of hyaluronic acid based derma fillers for Fiscal 2008. "At the same time, adds Mr Khoshbin, we anticipate that our growth will accelerate in Fiscal 2009 and beyond as a result of our aggressive product development activities over the past two years".

Explains Mr. Khoshbin, "As we roll out new proprietary branded products for Mesotherapy and Skin Care at the IMCAS trade show in Paris in January, 2009, it will become evident that our product pipeline is rich in new proprietary anti-aging and aesthetic product formulations. These products, coupled with our fast growing Revanesse® brand, widely used by physicians and clinicians in treating facial aesthetic patients, should have a profound impact on revenue growth and profitability for Fiscal 2009".

"At the same time, we recognize that the global marketplace for hyaluronic acid based aesthetic products is becoming increasingly competitive" explains Mr. Khoshbin. "This is precisely why we have intensified our product development activities to introduce new and improved branded products and expanded our sales and marketing efforts to ensure that our branded anti-aging and aesthetic products achieve broad acceptance in major global markets we currently serve as well as other new potentially lucrative markets that we wish to enter in 2009 and beyond."

Established in 2008 and headquartered in Amsterdam, Holland, AuraGenix currently designs, develops, markets and distributes through its wholly owned subsidiary, AuraGenix BioPharma, Malta, proprietary and uniquely formulated specialty pharma products for the anti-aging and facial aesthetics marketplace. The company's core line of hyaluronic acid based derma fillers are sold under the Revanesse® brand and distributed in more than 30 countries worldwide.

AuraGenix N.V. is an Affiliate of Prollenium Medical Technologies, Inc., Aurora, Ontario, Canada, that is a leading innovator in the design, development and manufacture of cutting edge products for the anti-aging and aesthetics marketplace.

Shares of AuraGenix N.V. are listed on the Open Market segment of the Frankfurt Exchange. A public offering of AuraGenix shares was not made in connection with their inclusion on the Open Market Frankfurt.